Marco Stojanovik Following a review of clinical trial results and consultation with external advisors, the Food and Drug Administration (FDA) has granted approval for Spravato to be used in patients with treatment-resistant depression in the United States. Spravato is a nasal spray produced by Janssen Pharmaceuticals Inc. that contains esketamine hydrochloride, a chemical mirror to […]